World Library  
Flag as Inappropriate
Email this Article

2-Methoxyethyl-18-methoxycoronaridinate

Article Id: WHEBN0028683471
Reproduction Date:

Title: 2-Methoxyethyl-18-methoxycoronaridinate  
Author: World Heritage Encyclopedia
Language: English
Subject: 18-Methylaminocoronaridine, 18-Methoxycoronaridine, Iboga, Cholinergics, Ganglionic blocker
Collection: Alkaloids, Drug Rehabilitation, Iboga, Nicotinic Antagonists
Publisher: World Heritage Encyclopedia
Publication
Date:
 

2-Methoxyethyl-18-methoxycoronaridinate

2-Methoxyethyl-18-methoxycoronaridinate
Clinical data
Legal status
?
Identifiers
ATC code ?
PubChem
ChemSpider  YesY
Chemical data
Formula C24H32N2O4 
Mol. mass 412.521 g/mol
 YesY   

(–)-2-Methoxyethyl-18-methoxycoronaridinate (ME-18-MC) is a second generation synthetic derivative of ibogaine developed by the research team led by the pharmacologist Stanley D. Glick from the Albany Medical College and the chemist Martin E. Kuehne from the University of Vermont.[1] In animal studies it has shown similar efficacy to the related compound 18-methoxycoronaridine (18-MC) at reducing self-administration of morphine and methamphetamine but with higher potency by weight, showing anti-addictive effects at the equivalent of half the minimum effective dose of 18-MC. Similarly to 18-MC itself, ME-18-MC acts primarily as a selective α3β4 nicotinic acetylcholine antagonist, although it has a slightly stronger effect than 18-MC as an NMDA antagonist, and its effects on opioid receptors are weaker than those of 18-MC at all except the kappa opioid receptor, at which it has slightly higher affinity than 18-MC.[2][3]

See also

References

  1. ^ Stanley D. Glick, Martin E. Kuehne. Ibogamine congeners. US Patent 6211360
  2. ^ Kuehne, ME; He, L; Jokiel, PA; Pace, CJ; Fleck, MW; Maisonneuve, IM; Glick, SD; Bidlack, JM (2003). "Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents". Journal of Medical Chemistry 46 (13): 2716–30.  
  3. ^ Pace, CJ; Glick, SD; Maisonneuve, IM; He, LW; Jokiel, PA; Kuehne, ME; Fleck, MW (2004). "Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration". European Journal of Pharmacology 492 (2–3): 159–67.  
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 



Copyright © World Library Foundation. All rights reserved. eBooks from World eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.